NEWS
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
SciSparc (Nasdaq: SPRC) has announced promising results from a study on 5-methoxy-2-aminoindane (MEAI), conducted in collaboration with Clearmind Medicine Inc. (Nasdaq: CMND). The study, published in ACS Pharmacology and Translational Science, demonstrates MEAI's potential as a novel weight loss drug. Key findings include:
Significant weight loss in diet-induced obese mice
Improved glucose metabolism and increased energy expenditure
Decreased fatty liver and reduced fat accumulation
Well-tolerated combination treatment with elevated metabolic processes
This research is part of SciSparc and Clearmind's ongoing collaboration since 2022, focusing on developing innovative treatments for addictions, obesity, and metabolic syndrome by combining SciSparc's Palmitoylethanolamide (PEA) with Clearmind's MEAI.
SciSparc (Nasdaq: SPRC) has announced promising results from a study on 5-methoxy-2-aminoindane (MEAI), conducted in collaboration with Clearmind Medicine Inc. (Nasdaq: CMND). The study, published in ACS Pharmacology and Translational Science, demonstrates MEAI's potential as a novel weight loss drug. Key findings include:
Significant weight loss in diet-induced obese mice
Improved glucose metabolism and increased energy expenditure
Decreased fatty liver and reduced fat accumulation
Well-tolerated combination treatment with elevated metabolic processes
This research is part of SciSparc and Clearmind's ongoing collaboration since 2022, focusing on developing innovative treatments for addictions, obesity, and metabolic syndrome by combining SciSparc's Palmitoylethanolamide (PEA) with Clearmind's MEAI.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1161Followers
73Following
8092Visitors
Follow